Zapping kidney nerves may tame tough blood pressure
NCT ID NCT04264403
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a device that uses ultrasound to calm overactive nerves in the kidneys, which can drive high blood pressure. Researchers enrolled 44 people with stage 3 chronic kidney disease and uncontrolled hypertension. Half received the real procedure, half a sham, to see if it safely lowers 24-hour blood pressure readings.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- renal denervation device (Paradise® System) that uses ultrasound energy to calm kidney nerves
- What this could lead to
- If it works, this could offer a new way to control blood pressure in people with chronic kidney disease without adding more pills.
- What could go wrong
- This was a small, early feasibility study with only 44 participants, so results may not apply to everyone. The procedure carries risks like blood vessel damage or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
44 people
The number who actually took part.
- Started
-
Jan 2020
- Finished
-
Apr 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * CKD stage 3 (eGFR 30-59 ml/min/1.73m² \[according to the currently used estimation formulas: MDRD, CKD-EPI\]) with diabetic or non-diabetic nephropathy * Uncontrolled hypertension with 1-5 drug classes (renin angiotensin system \[RAS\] blockade is mandatory, unless intolerance to RAS blockers has been documented) and systolic office (attended) BP ≥140 mmHg confirmed by 24-h ambulatory BP systolic ≥130 mmHg * Patient is adhering to a stable drug regimen including RAS blockade without changes for a minimum of 4 weeks. * Individual is ≥ 18 years of age, both genders are included. Exclusion Criteria: * Anatomically significant renal artery abnormality in either renal artery which in the eyes of the interventionalist would interfere with safe catheter Placement * Other cause of Hypertension that can be treated by Intervention/surgery (e.g. hemodynamically relevant renal artery stenosis, functional adrenal adenoma) * Prior renal denervation procedure * Office (attended) BP ≥ 180 mmHg systolic and/or ≥ 110 mmHg diastolic * 24-h ambulatory BP ≥ 160 mmHg systolic * Anatomic or functional solitary kidney, kidney transplantation * Lack of capturing serum creatinine levels in the past * Secondary hypertension other than obstructive sleep apnea * Type 1 diabetes mellitus * Nephrotic syndrome * Contraindication to magnetic resonance imaging (MRI) * Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit * Acute episode of renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months * Subject is pregnant, nursing, or intends to become pregnant * Enrollment in another interventional research protocol. * Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease STAGE3 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Center Nuremberg, Department of Nephrology, University Hospital Erlangen
Nuremberg, Germany
-
Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg
Erlangen, 91054, Germany
-
Heinrich Heine University Düsseldorf, Nephrologie, Germany
Düsseldorf, 40225, Germany
-
Klinik für Innere Medizin III, Kardiologie, Angiologie Und Internistische Intensivmedizin, Saarland University Hospital, Saarland University
Homburg, 66421, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Neck implant aims to tame stubborn high blood pressure
- Can a new pill tame blood pressure that Won't budge?
- Zapping kidney nerves: a new hope for stubborn high blood pressure?
- New drug aims to tame stubborn high blood pressure
- New pill aims to tame stubborn high blood pressure
- Why kidney patients feel so tired: muscle fatigue under the microscope